Clinical application of CD19-targeted CAR-T therapy in non-hematologic solid tumors

Establish whether CD19-targeted chimeric antigen receptor T-cell therapy is clinically safe and efficacious in non-hematologic solid tumors by conducting clinical studies that evaluate antitumor activity, toxicity, dosing, and treatment feasibility.

Background

CD19-targeted CAR-T therapies have demonstrated high efficacy in B-cell malignancies, and this paper presents preclinical data suggesting potential benefit in hepatocellular carcinoma via depletion of CD19+ TAMs.

However, the authors explicitly state that the clinical application of CD19 CAR-T cells in non-hematologic solid tumors has not been established, underscoring the need for rigorous clinical evaluation.